Efficacy of mFOLFOX6 or XELOX and bevacizumab for the treatment of colorectal cancer associated with resectable synchronous liver metastasis in patients undergoing hepatectomy

Trial Profile

Efficacy of mFOLFOX6 or XELOX and bevacizumab for the treatment of colorectal cancer associated with resectable synchronous liver metastasis in patients undergoing hepatectomy

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top